Health Catalyst, Inc. (NASDAQ:HCAT) Receives $2.45 Average Target Price from Analysts

Health Catalyst, Inc. (NASDAQ:HCAT) has been given a consensus recommendation of “Hold” by the eleven brokerages that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $2.45.

A number of research firms have commented on HCAT. Canaccord Genuity Group reissued a “hold” rating and issued a $1.80 target price (down from $3.00) on shares of Health Catalyst in a report on Thursday, August 20th. Weiss Ratings raised shares of Health Catalyst from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. Wells Fargo & Company cut their price target on shares of Health Catalyst from $1.75 to $1.50 and set an “equal weight” rating for the company in a report on Thursday, August 13th. Finally, Citigroup reduced their price objective on shares of Health Catalyst from $2.50 to $2.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th.

Health Catalyst Price Performance

Shares of HCAT opened at $1.70 on Friday. The company has a current ratio of 2.70, a quick ratio of 2.70 and a debt-to-equity ratio of 1.51. The stock’s 50 day moving average is $1.93 and its two-hundred day moving average is $1.64. Health Catalyst has a twelve month low of $0.96 and a twelve month high of $3.62. The firm has a market capitalization of $127.94 million, a PE ratio of -0.46 and a beta of 1.53.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Thursday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.01. Health Catalyst had a negative return on equity of 1.83% and a negative net margin of 90.61%.The business had revenue of $70.49 million during the quarter, compared to the consensus estimate of $69.09 million. Research analysts anticipate that Health Catalyst will post -0.18 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new stake in shares of Health Catalyst during the 4th quarter valued at approximately $25,000. Visionary Wealth Advisors acquired a new stake in shares of Health Catalyst in the 2nd quarter worth approximately $27,000. AXQ Capital LP acquired a new stake in shares of Health Catalyst in the 2nd quarter worth approximately $38,000. Cresset Asset Management LLC purchased a new position in Health Catalyst in the 2nd quarter valued at approximately $39,000. Finally, Deutsche Bank AG purchased a new position in Health Catalyst in the 2nd quarter valued at approximately $43,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.